Remove 2015 Remove Competition Remove Leads
article thumbnail

Pharma is big business whose goal is to maximize shareholder value

World of DTC Marketing

From 2016 to 2020, the 14 leading drug companies spent $577 billion on stock buybacks and dividends—$56 billion more than they spent on R&D over the same period.” In a 2015 study of 36 cancer drugs that had recently been approved, only 5 showed extended life. Big pharma is big business. Here’s another example.

Pharma 292
article thumbnail

Is the launch environment really more competitive now?

pharmaphorum

It’s often stated – mostly without reference to data – that the environment for innovative launches is more competitive now than it ever has been. A second, “transitional era” from 2000-2015 was one of older specialty products, including those in multiple sclerosis, early immunological biologics, and oncologics.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Harnessing the Power of Generational Diversity as a Competitive Advantage

PM360

Today’s workforce includes Traditionalists (born 1927-1945), Boomers (1946-1964), Gen X (1965-1980), Millennials (1981-1996), and Gen Z (1997-2015). Marketing and comms teams that go beyond simply accepting generational differences by leveraging them proactively will lead to increased engagement, innovation, and organizational success.

article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Observational studies should not be seen as competition to RCTs but as complementary to them, and as a sector we need to stop working in silos and develop an integrated and more comprehensive approach to evidence-based decision-making in safeguarding public health. Guide on Methodological Standards in Pharmacoepidemiology (Revision 11).

Medicine 116
article thumbnail

Global comparator data signal “alarm bells” for UK Government, says APBI

pharmaphorum

Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Richard Torbett, chief executive at the Association of the British Pharmaceutical Industry (ABPI) said Life Sciences Competitive Indicators (LSCI) data published last week “ought to ring alarm bells across Government”.

article thumbnail

Is the pharmaceutical sector realising its potential for sustainable manufacturing?

European Pharmaceutical Review

Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available. Creating more sustainable business processes is a pre-competitive activity; we all win when we make progress in sustainability and lose if we don’t. References Belkhir L, Elmeligi A.

article thumbnail

The EU HTA regulation: a new frontier for access to innovative technologies

European Pharmaceutical Review

Article 15 proved that transparent and effective assessments of new technologies were crucial to ensure fair competition between stakeholders that operate in the EU. This essentially means that the technologies to be assessed will be considered innovative if they offer advantages over existing similar products – especially in terms of cost?effectiveness